作者
Kentaro Matsui, Takahiro Tokumasu, Yoshiteru Takekita, Ken Inada, Tetsufumi Kanazawa, Taishiro Kishimoto, Shotaro Takasu, Hideaki Tani, Seiichiro Tarutani, Naoki Hashimoto, Hiroki Yamada, Yoshio Yamanouchi, Hiroyoshi Takeuchi
发表日期
2019/7/1
来源
Schizophrenia research
卷号
209
页码范围
50-57
出版商
Elsevier
简介
Background
While recent meta-analyses have reported the superiority of antipsychotic polypharmacy (APP) over antipsychotic monotherapy (APM) in schizophrenia, switching to APM can be beneficial in terms of side effects. To determine whether patients receiving APP should switch to APM or stay on APP, we conducted a systematic review and meta-analysis.
Methods
Randomized controlled trials (RCTs) examining a switch from APP to APM vs. staying on APP were systematically selected from a previous meta-analysis comparing APP with APM in patients with schizophrenia. In addition, we conducted an updated systematic literature search using MEDLINE, Embase, and Cochrane Central Register of Controlled Trials. Data on study discontinuation, relapse, psychopathology, neurocognition, extrapyramidal symptoms, and body weight/body mass index (BMI) were extracted and synthesized.
Results
A total of 6 …
学术搜索中的文章
K Matsui, T Tokumasu, Y Takekita, K Inada… - Schizophrenia research, 2019